Month: September 2020

Carey Hendrickson to Step Down on November 6, 2020Company Initiates Search for a SuccessorDALLAS, Sept. 21, 2020 (GLOBE NEWSWIRE) — Capital Senior Living Corporation (the “Company”) (NYSE: CSU), one of the nation’s largest operators of senior living communities, today announced that Carey Hendrickson, Executive Vice President and Chief Financial Officer, will step down from his position to pursue another opportunity. To ensure a smooth transition, Mr. Hendrickson will remain in his current role through November 6, 2020. The Company has initiated a comprehensive search for a successor and has retained a leading executive search firm to assist with the process.“We thank Carey for his numerous contributions to the company during his tenure as CFO,” said Kimberly S. Lody, President and Chief Executive Officer. “He has been a valued...

SHANGHAI, China, Sept. 21, 2020 (GLOBE NEWSWIRE) — Qutoutiao Inc. (“Qutoutiao”, the “Company” or “We”) (NASDAQ: QTT), a leading operator of mobile content platforms in China, today announced its unaudited financial results in the second quarter ended June 30, 2020.Second Quarter 2020 HighlightsCombined average MAUs1 were 136.5 million, compared to 119.3 million in the second quarter of 2019 and 138.3 million in the first quarter of 2020.Combined average DAUs2 were 43.0 million, compared to 38.7 million in the second quarter of 2019 and 45.6 million in the first quarter of 2020.Average daily time spent per DAU was 55.2 minutes, compared to 60.0 minutes in the second quarter of 2019 and 62.4 minutes in the first quarter of 2020.Net revenues increased 4.0% year-over-year to RMB1,441.0 million (US$204.0 million), compared to RMB1,411.8...

NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) — The Nasdaq Stock Market announced today that it will delist the American Depositary Shares, of Therapix Biosciences Ltd.  Therapix Biosciences Ltd.’s American Depositary Shares were suspended on July 2, 2020 and have not traded on Nasdaq since that time.Nasdaq also announced today that it will delist the common stock of Stein Mart, Inc.  Stein Mart, Inc.’s common stock was suspended on August 24, 2020 and has not traded on Nasdaq since that time.Nasdaq also announced today that it will delist the common stock of Shiloh Industries, Inc.  Shiloh Industries, Inc.’s common stock was suspended on September 10, 2020 and has not traded on Nasdaq since that time.Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delistings. The delistings become effective ten...

SILVER SPRING, Md., Sept. 21, 2020 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today that Maybelle Jordan, Vice President of Business Development of Biomerix Corporation, and Brigid Makes, former Senior Vice President and Chief Financial Officer of Miramar Labs, have joined its board of directors.Maybelle Jordan has served as Vice President of Business Development of Biomerix Corporation, a biomaterials company focused on scaffold technology in the medical technology industry, since 2011, and as Chief Operating Officer for Biomerix from 2003 to 2011. She also co-founded and served as President and CEO of MTrap Inc., a clinical-stage biomaterials...

New analysis of age-related macular degeneration (AMD) progression in Phase 2 FILLY study accepted as late-breaking oral presentation at European Society of Retina Specialists Congress (EURETINA)Pegcetacoplan targets C3, and has the potential to control the irreversible lesion growth in GA, an advanced form of AMD and leading cause of blindnessWALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that a post hoc analysis of the Phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETINA 2020 Virtual.This new analysis of the FILLY study...

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the closing of its initial public offering of 14,089,314 shares of its common stock at an initial public offering price of $19.00 per share, including 1,837,736 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Dyne. The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Dyne, were approximately $268 million.The shares began trading on the Nasdaq Global Select Market on Thursday, September...

SUNNYVALE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it is strengthening its leadership team with two appointments. William Whealon, Ph.D. has joined the company as Executive Vice President of Research and Development, effective immediately. Silk Road Medical has also named Lucas Buchanan, the company’s current Chief Financial Officer, to also serve as its Chief Operating Officer, effective October 1, 2020.“We are excited to welcome Bill to Silk Road Medical as we further strengthen our leadership team. His proven track record for building and leading effective and innovative R&D groups and his passion for identifying solutions to solve unmet clinical needs will be instrumental in our continued...

Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)NUC-3373’s Favorable Pharmacokinetic and Safety Profile Unaffected by LeucovorinFirst-in-Human Data of NUC-7738 Shows Anti-Cancer Activity and a Favorable Tolerability ProfileEDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA), announced data from the ongoing NUC-3373 and NUC-7738 clinical programs, as well as a review of the ongoing Acelarin Phase III study, at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.NUC-3373 is NuCana’s targeted inhibitor of thymidylate synthase designed to overcome the main challenges associated with 5-FU including cancer resistance mechanisms, off-target toxicity and administration burdens. Data from...

SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) — Grindrod Shipping Holdings Ltd. (NASDAQ: GRIN) (JSE: GSH) (“Grindrod Shipping” or “Company” or “it” or “we”), a global provider of maritime transportation services in the drybulk and product tanker sectors, announced two transactions with respect to its fleet.On September 15, 2020, the Company took delivery of the IVS Pebble Beach, a Japanese-built eco ultramax drybulk carrier newbuilding. As previously disclosed, the vessel has been chartered-in from its owner for a minimum period of two years with options to extend for up to two additional years, at Grindrod Shipping’s election. In addition, the Company holds options to purchase the vessel in the future.On September 2, 2020, the previously announced sale of the 2004-built handysize drybulk carrier IVS Nightjar was completed, with the...

IRVINE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the interim results from the FLASH study have been accepted for presentation in a late-breaking clinical science session at TCT Connect. The FLASH study is evaluating the safety and effectiveness of the FlowTriever System for treatment of pulmonary embolism (PE) in a real-world patient population. Interim data on the first 230 patients enrolled at 19 US sites will be presented in the late-breaking session.“We are excited to feature the interim FLASH data as part of a late-breaking session at TCT Connect,” said Thomas Tu, MD, Chief Medical Officer of Inari Medical. “FLASH...